Vaccinated children and adolescents with pertussis infections experience reduced illness severity and duration, Oregon, 2010-2012

Clinical Infectious Diseases

Volumn 58, Issue 11, 2014, Pages 1523-1529

  Barlow, Russell S ^a,b,c   Reynolds, Laura E ^a   Cieslak, Paul R ^d   Sullivan, Amy D ^a  

^a MULTNOMAH COUNTY HEALTH DEPARTMENT   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d OREGON HEALTH AUTHORITY   (United States)

Author keywords

Bordetella pertussis; Epidemic; Epidemiology; Surveillance; Vaccines

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; PERTUSSIS VACCINE;

ADOLESCENT; ADULT; ARTICLE; BORDETELLA PERTUSSIS; CHILD; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HEALTH SURVEY; HUMAN; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PERTUSSIS; PRIORITY JOURNAL; UNITED STATES; VACCINATION; EPIDEMIOLOGICAL MONITORING; EPIDEMIOLOGY; HOSPITALIZATION; PATHOLOGY; PRESCHOOL CHILD; SEVERITY OF ILLNESS INDEX; TIME; WHOOPING COUGH;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; EPIDEMIOLOGICAL MONITORING; FEMALE; HOSPITALIZATION; HUMANS; INFANT; MALE; OREGON; PERTUSSIS VACCINE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; WHOOPING COUGH;

EID: 84900408036     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu156     Document Type: Article

References (32)

1. von König CH, Halperin S, Riffelmann M, Guiso N. Pertussis of adults and infants. Lancet Infect Dis 2002; 2:744-50.
2. Lee GM, Lett S, Schauer S, et al. Massachusetts Pertussis Study Group. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis 2004; 39:1572-80.
3. Lee GM, Lebaron C, Murphy TV, Lett S, Schauer S, Lieu TA. Pertussis in adolescents and adults: should we vaccinate? Pediatrics 2005; 115:1675-84.
4. Tanaka M, Vitek CR, Pascual FB, Bisgard KM, Tate JE, Murphy TV. Trends in pertussis among infants in the United States, 1980-1999. JAMA 2003; 290:2968-75.
5. Centers for Disease Control and Prevention. Vaccination coverage among children in kindergarten. United States, 2009-10 school year. MMWR Morb Mortal Wkly Rep 2011; 60:700-4
6. Centers for Disease Control and Prevention (CDC). Summary of notifiable diseases: United States, 2009. MMWR Morb Mortal Wkly Rep 2011; 58:1-100.
7. Centers for Disease Control and Prevention. Use of diphtheria toxoidtetanus toxoid-acellular pertussis vaccine as a five-dose series: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1-8.
8. Centers for Disease Control and Prevention. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2006; 55:1-43.
9. Centers for Disease Control and Prevention. Pertussis (whooping cough). Fast facts. 2012. Available at: http://www.cdc.gov/pertussis/fast-facts.html. Accessed 18 July 2013.
10. Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 2012; 54:1730-5.
11. Misegades LK, Winter K, Harriman K, et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 2012 308:2126-32.
12. Tartof SY, Lewis M, Kenyon C, et al.Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 2013; 131:e1047-52.
13. Witt MA, Arias L, Katz PH, Truong ET, Witt DJ. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort. Clin Infect Dis 2013; 56:1248-54.
14. Centers for Disease Control and Prevention. Pertussis epidemic-Washington, 2012. MMWR Morb Mortal Wkly Rep 2012; 61:517-22.
15. Oregon Health Authority. Pertussis update. CD Summary 2012; 61.
16. Grob PR, Crowder MJ, Robbins JF. Effect of vaccination on severity and dissemination of whooping cough. Br Med J (Clin Res Ed) 1981; 282:1925-8.
17. Préziosi MP, Halloran ME. Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity. Clin Infect Dis 2003; 37:772-9.
18. Council of State and Territorial Epidemiologists (CSTE). 1997 position statements. In: CSTE National Meeting, Saratoga Springs, NY. Position statement 9. Available at: http://c.ymcdn.com/sites/www.cste.org/resource/resmgr/PS/1997- Id-9.pdf.
19. Portland State University Population Research Center. Available at: http:// pdx.edu/prc/population-estimates-0. Accessed 29 November 2012.
20. United States Census 2010. Available at: http://quickfacts.census.gov/ qfd/states/41/41051.html. Accessed 18 July 2013.
21. Centers for Disease Control and Prevention. Vaccination coverage among children in kindergarten-United States, 2012-13 school year. MMWR Morb Mortal Wkly Rep 2013; 62;607-12.
22. Bortolussi R, Miller B, Ledwith M, Halperin S. Clinical course of pertussis in immunized children. Ped Infect Dis J 1995; 14:870-4.
23. Centers for Disease Control and Prevention, National Immunization Program. Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC guidelines. MMWR Recomm Rep 2005; 54:1-16.
24. Misegades LK, Martin SW, Messonnier NE, Clark TA. Estimating the effectiveness of acellular pertussis vaccines. Clin Infect Dis 2012; 55:1432-3; author reply 1435-6.
25. Meyer CU, Habermehl P, Knuf M, Hoet B, Wolter J, Zepp F. Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children: standard pediatric versus a reduced-antigen content formulation. Hum Vaccin 2008; 4:203-9.
26. Schure RM, Hedrikx LH, de Rond LG, et al. T-cell responses before and after the fifth consecutive acellular pertussis vaccination in 4-year-old Dutch children. Clin Vaccine Immunol 2012; 19:1879-86.
27. Hendrikx LH, Berbers GA, Veenhoven RH, Sanders EA, Buisman AM. IgG responses after booster vaccination with different pertussis vaccines in Dutch children 4 years of age: effect of vaccine antigen content. Vaccine 2009; 27:6530-6.
28. Moore MR, Gertz RE Jr, Woodbury RL, et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis 2008; 197:1016-27.
29. Marr N, Luu RA, Fernandez RC. Bordetella pertussis binds human C1 esterase inhibitor during the virulent phase, to evade complement-mediated killing. J Infect Dis 2007; 195:585-8.
30. Barnes MG, Weiss AA. BrkA protein of Bordetella pertussis inhibits the classical pathway of complement after C1 deposition. Infect Immun 2001; 69:3067-72.
31. Guris D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999; 28:1230-7.
32. Centers for Disease Control and Prevention. National and state vaccination coverage among children aged 19-35 months-United States, 2010. MMWR Morb Mortal Wkly Rep 2011; 60:1157-63.